SECOND QUARTER August 1 – October 31, 2013
- Consolidated Net sales amounted to € 3 thousand (0)[1]
- Operating income amounted to € -1,974 thousand (-1,469)
- Net income after tax amounted to € -2,120 thousand (-1,655)
- Earnings per share amounted to € -0.03 (-0.03)
- Comprehensive income amounted to € -2,120 thousand (-1,655)
THE PERIOD May 1 – October 31, 2013
- Consolidated Net sales amounted to € 3 thousand (0)
- Operating income amounted to € -3,903 thousand (-3,552)
- Net income after tax amounted to € -4,190 thousand (-3,850)
- Earnings per share amounted to € -0.05 (-0.07)
- Comprehensive income amounted to € -4,190 thousand (-3,850)
- Oasmia initiated a clinical program for Paclical for treatment of breast cancer
- Oasmia initiated pre-clinical studies with OAS-19, the first pharmaceutical project with a combination of two active cytostatics in one infusion
EVENTS AFTER CLOSING DAY
- Increased funding through extension of MSEK 105 loan from Nexttobe and a new MSEK 40 bank loan
- Oasmia Announces Successful FDA Pre-Approval Inspection of Its Manufacturing Facility
CEO COMMENTS:
”During the second quarter we continued to work with both pre-clinical and clinical studies of our prioritized projects. Also, we have noted a continued interest for our patented technology platform XR-17 among other pharmaceutical companies looking for an excipient for their projects with insoluble pharmaceuticals”, says CEO Julian Aleksov.
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company share is listed at NASDAQ OMX in Stockholm and at the Frankfurt Stock Exchange.